GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting

May 18, 2018 Updated patient durability results from proof-of-concept trial presented; reductions in incontinence episodes continue to be sustained for up to 7 months following completion of enobosarm treatment Top-line results from ASTRID, an ongoing Phase 2 placebo-controlled clinical trial,